Soligenix prices $7.5 million public offering at $1.35 per share

Soligenix Inc. (NASDAQ: SNGX) announced the pricing of a public offering for 5,555,560 shares of common stock and accompanying warrants at $1.35 per share and warrant, according to a company statement.

The biopharmaceutical company expects to raise approximately $7.5 million in gross proceeds before deducting placement agent fees and other offering expenses. The offering is expected to close on or about September 29, 2025, subject to customary closing conditions.

The warrants carry an exercise price of $1.35 per share, are exercisable immediately, and will expire five years from the issuance date. Soligenix also agreed to amend certain existing warrants from May 2023, April 2024, and July 2024 to reduce their exercise price to $1.35 per share with expiration dates matching the new warrants.

A.G.P./Alliance Global Partners is serving as the sole placement agent for the transaction. The company intends to use the net proceeds for research and development, commercialization activities, working capital, and general corporate purposes.

The offering is being conducted under a registration statement on Form S-1 filed with the Securities and Exchange Commission on September 19, 2025, which became effective on September 25, 2025.

Princeton, New Jersey-based Soligenix focuses on developing treatments for rare diseases with unmet medical needs. The company operates two business segments: Specialized BioTherapeutics, which includes photodynamic therapy treatments, and Public Health Solutions, which develops vaccines for biodefense applications.

You May Also Be Interested In

• AEVEX prices public offering of 8 million shares at $27 each
• FDA grants fast track status to Verastem's lung cancer drug VS-7375
• Celcuity announces $400 million convertible notes offering due 2032